自身免疫性肝炎的标准治疗和潜在治疗靶点

王睿; 王绮夏; 马雄

doi:10.3969/j.issn.1001-5256.2020.04.005

自身免疫性肝炎的标准治疗和潜在治疗靶点

DOI: 10.3969/j.issn.1001-5256.2020.04.005

上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所

基金项目:

国家自然科学基金项目(81770564,81790634,81620108002,81771732,81830016)；上海市卫生计生系统优秀青年医学人才培养计划(2017YQ037)；上海市青年科技启明星计划(18QA1402700)；

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1857
- HTML全文浏览量: 54
- PDF下载量: 402
- 被引次数: 0
出版历程
- 收稿日期: 2020-02-07
- 出版日期: 2020-04-20

Standard therapy and potential therapeutic targets for autoimmune hepatitis

Division of Gastroenterology and Hepatology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University & Shanghai Institute of Digestive Diseases

Research funding:

摘要

摘要: 自身免疫性肝炎(AIH)是一种由自身免疫反应介导的肝脏炎症性疾病,未经积极治疗可发展为肝衰竭、肝硬化。AIH的治疗目标为获得生化缓解和组织学缓解。目前标准治疗方案为免疫抑制剂疗法,即泼尼松(龙)联合硫唑嘌呤或泼尼松(龙)单药治疗。患者对标准治疗方案不耐受或应答不佳时,可考虑启动包括吗替麦考酚酯在内的二线治疗方案。近年来研究表明,免疫功能、肠道菌群、维生素D、心理状态等多种因素参与AIH的发生发展,可作为AIH的潜在治疗靶点。综述了近年来AIH治疗方案的相关研究及潜在治疗靶点。
- 肝炎,自身免疫性 /
- 治疗学 /
- 分子靶向治疗
Abstract: Autoimmune hepatitis( AIH) is a liver inflammatory disease mediated by autoimmune response and may progress to liver failure and liver cirrhosis without treatment. The goal of AIH treatment is to achieve biochemical remission and histological remission. Currently immunosuppressant therapy is the standard therapy for AIH,i. e.,prednisone/prednisolone alone or combined with azathioprine. For the patients who do not tolerate or have poor response to the standard therapy,second-line treatment regimen,including mycophenolate mofetil,can be considered. Recent studies have shown that various factors participate in the development and progression of AIH,such as immune function,gut microbiota,vitamin D,and mental state,which may become the potential therapeutic targets for AIH. This article reviews related studies on the standard therapies for AIH and highlights the potential therapeutic targets for AIH treatment.
- hepatitis,autoimmune /
- therapeutics /
- molecular targeted therapy

HTML全文

参考文献(51)

[1] KRAWITT EL. Autoimmune hepatitis[J]. N Engl J Med,2006,354(1):54-66.

[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.

[3] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.

[4] DYSON JK,WONG LL,BIGIRUMURAME T,et al. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom[J]. Aliment Pharmacol Ther,2018,48(9):951-960.

[5] van GERVEN NM,VERWER BJ,WITTE BI,et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission[J]. J Hepatol,2013,58(1):141-147.

[6] LOHSE AW,MIELI-VERGANI G. Autoimmune hepatitis[J]. J Hepatol,2011,55(1):171-182.

[7] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the study of liver diseases[J]. Hepatology,2019.[Epub ahead of print]

[8] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. e1.

[9] BINICIER OB,GNAY S. The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis:A retrospective study[J]. Croat Med J,2019,60(4):345-351.

[10] ZACHOU K,GATSELIS NK,ARVANITI P,et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis[J]. Aliment Pharmacol Ther,2016,43(10):1035-1047.

[11] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.

[12] ROBERTS SK,LIM R,STRASSER S,et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy[J]. Clin Gastroenterol Hepatol,2018,16(2):268-277.

[13] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.

[14] GIANNAKOPOULOS G,VERBAAN H,FRIIS-LIBY IL,et al.Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine[J]. Dig Liver Dis,2019,51(2):253-257.

[15] THAN NN,WIEGARD C,WEILER-NORMANN C,et al. Longterm fol ow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy[J]. Scand J Gastroenterol,2016,51(3):329-336.

[16] AL TAII H,HANOUNEH MA,HANOUNEH I,et al. The use of tacrolimus in refractory autoimmune hepatitis in children and adults:A single center experience[J]. Scand J Gastroenterol,2017,52(2):157-158.

[17] HBENER S,OO YH,THAN NN,et al. Efficacy of 6-Mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance[J]. Clin Gastroenterol Hepatol,2016,14(3):445-453.

[18] LEGUC,LEGROS L,KAMMERER-JACQUET S,et al. Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):290-291.

[19] HARIDY J,NICOLL A,SOOD S. Methotrexate therapy for autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):288-289.

[20] CAMPSEN J,ZIMMERMAN MA,TROTTER JF,et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal[J]. Liver Transpl,2008,14(9):1281-1286.

[21] FERRI S,LONGHI MS,de MOLO C,et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1autoimmune hepatitis[J]. Hepatology,2010,52(3):999-1007.

[22] CHEN YY,JEFFERY HC,HUNTER S,et al. Human intrahepatic regulatory T cells are functional,require IL-2 from effector cells for survival,and are susceptible to Fas ligand-mediated apoptosis[J]. Hepatology,2016,64(1):138-150.

[23] DANIEL V,TROJAN K,OPELZ G. Immunosuppressive drugs affect induction of IFNy+Treg in vitro[J]. Hum Immunol,2016,77(1):146-152.

[24] LIM TY,MARTINEZ-LLORDELLA M,KODELA E,et al. Lowdose interleukin-2 for refractory autoimmune hepatitis[J]. Hepatology,2018,68(4):1649-1652.

[25] NISHIKAWA H,ENOMOTO H,IWATA Y,et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-γ-inducible protein-10 in autoimmune hepatitis[J]. Medicine(Baltimore),2016,95(12):e3194.

[26] CHEN L,LU FB,CHEN DZ,et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis[J]. Mol Immunol,2018,93:38-46.

[27] WU H,LIAO W,LI Q,et al. Pathogenic role of tissue-resident memory T cells in autoimmune diseases[J]. Autoimmun Rev,2018,17(9):906-911.

[28] LIAN M,ZHANG J,ZHAO L,et al. Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells[J]. Front Immunol,2019,10:2577.

[29] WEBB GJ,HIRSCHFIELD GM,KRAWITT EL,et al. Cellular and molecular mechanisms of autoimmune hepatitis[J]. Annu Rev Pathol,2018,13:247-292.

[30] VALGEIRSSON KB,HREINSSON JP,BJRNSSON ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs[J]. Liver Int,2019,39(12):2341-2349.

[31] NEURATH M. Current and emerging therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol,2017,14(11):688.

[32] DIESTELHORST J,JUNGE N,JONIGK D,et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep,2018,8(1):419.

[33] AOKI N,KIDO M,IWAMOTO S,et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice[J]. Gastroenterology,2011,140(4):1322-1333. e1-e5.

[34] LONGHI MS,HUSSAIN MJ,BOGDANOS DP,et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2[J]. Hepatology,2007,46(2):472-484.

[35] UMESHAPPA CS,SINGHA S,BLANCO J,et al. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines[J]. Nat Commun,2019,10(1):2150.

[36] ELLEBRECHT CT,BHOJ VG,NACE A,et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science,2016,353(6295):179-184.

[37] MUCENIC M,MELLO ES,CANADO EL. Chloroquine for the maintenance of remission of autoimmune hepatitis:Results of a pilot study[J]. Arq Gastroenterol,2005,42(4):249-255.

[38] RAQUEL BENEDITA TERRABUIO D,AUGUSTO DINIZ M,TEOFILO DE MORAES FALCO L,et al. Chloroquine is effective for maintenance of remission in autoimmune hepatitis:Control ed,double-blind,randomized trial[J]. Hepatol Commun,2019,3(1):116-128.

[39] KORHONEN R,MOILANEN E. Abatacept,a novel CD80/86-CD28 T cell co-stimulation modulator,in the treatment of rheumatoid arthritis[J]. Basic Clin Pharmacol Toxicol,2009,104(4):276-284.

[40] LIU LL,FENG ML,WANG LN,et al. A case report of successful treatment with plasma exchange for adult-onset Still’s disease with autoimmune hepatitis[J]. J Clin Apher,2010,25(2):74-76.

[41] EFE C,PURNAK T,OZASLAN E. The diagnosis of autoimmune hepatitis in patients with adult-onset Still’s disease[J]. J Clin Apher,2010,25(4):235; author reply 236.

[42] LIN R,ZHOU L,ZHANG J,et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.

[43] WEI Y,LI Y,YAN L,et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut,2020,69(3):569-577.

[44] KESAR V,ODIN JA. Toll-like receptors and liver disease[J].Liver Int,2014,34(2):184-196.

[45] CZAJA AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis[J]. World J Gastroenterol,2016,22(42):9257-9278.

[46] WILCK N,MATUS MG,KEARNEY SM,et al. Salt-responsive gut commensal modulates TH17 axis and disease[J].Nature,2017,551(7682):585-589.

[47] HU ED,CHEN DZ,WU JL,et al. High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier[J]. Cell Immunol,2018,328:24-32.

[48] EFE C,KAV T,AYDIN C,et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis[J].Dig Dis Sci,2014,59(12):3035-3042.

[49] BAJAJ JS,ELLWOOD M,AINGER T,et al. Mindfulnessbased stress reduction therapy improves patient and caregiver-reported outcomes in cirrhosis[J]. Clin Transl Gastroenterol,2017,8(7):e108.

[50] PAIDAS MJ,ANNUNZIATO J,ROMANO M,et al. Pregnancy and multiple sclerosis(MS):A beneficial association. Possible therapeutic application of embryo-specific pre-implantation factor(PIF*)[J]. Am J Reprod Immunol,2012,68(6):456-464.

[51] HEGDE VL,NAGARKATTI PS,NAGARKATTI M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol[J]. PLo S One,2011,6(4):e18281.

施引文献

资源附件(0)

访问统计